We do not just analyze your data on its own, but also with datasets from other patients around the world.
Using machine learning and AI, we can quickly identify and predict any emerging trends or changing behaviors in your cancer. Catch it before it happens!
Accredited and approved
The liquid biopsy (cancer cells recovery) method is approved by FDA (USA), CE (Europe) and NMPA (China). All sample processing is performed in a Singapore laboratory licensed by the Ministry of Health. Analysis is done by our team at Harvard in USA.
We value the integrity of your sample to the utmost degree and thus make sure we go above and beyond all regulatory compliance standards.
We work with your oncologist
We don't replace your doctor. In fact we have no plans to replace anybody!
PathBright™ is a Clinical Decision Support tool that complements the oncologist's work by providing data-driven insights on your cancer. Your oncologist can then make informed and confident decisions that will increase the success rate, quality of care and enhance health outcomes.
Analyze the tumor directly
We analyze your tumor cells directly, and not other indirect biomarkers such as CEA, CA 19.9 or PSA.
Reveal hidden information
We use advanced imaging, machine learning and artificial intelligence to reveal information that you and your oncologist cannot see.
Get deeper insights
3D imaging of cancer cells can offer deeper dimensional and functional insights not seen elsewhere.
Diverse capabilities to help you
Multi-disciplinary approach in fighting cancer by integrating computer vision, AI and personalized medicine.
Monitoring of cancer can now be performed regularly and easily without pain.
We are from Harvard
We are a Harvard start-up, and a Finalist and Winner of Best Social Impact Award in Harvard Business School New Venture Competition 2020. =)
Who is suitable for PathBright™?
Newly diagnosed patients
Detect changes in cancer and evaluate treatment options.
Patients undergoing treatment
Determine the efficiency of the treatment.
Survivors (in remission)
Monitor cancer status and predict any emerging activity.